Interpret maternal red-cell antibodies, prevent avoidable sensitisation and organise antibody-specific fetal surveillance, transfusion planning and neonatal follow-up.
Red-cell alloimmunisation occurs when a person forms antibodies against an erythrocyte antigen they do not possess after exposure through pregnancy or transfusion. During pregnancy, clinically significant IgG antibodies can cross the placenta and affect a fetus carrying the relevant antigen. The term rhesus disease is therefore too narrow for the whole problem: anti-D is important, but anti-c, anti-K and several other specificities can cause fetal or neonatal harm. Screening also protects the mother by alerting the transfusion laboratory that compatible units may require additional preparation.
Begin with the exact laboratory report rather than a generic note saying antibodies present. Establish specificity, concentration or titre, whether the antibody was previously detected, transfusion history and the outcome of earlier pregnancies. Previous fetal anaemia, intrauterine transfusion, neonatal exchange transfusion or severe jaundice can outweigh a currently modest antibody result. Review the date, dose and route of every anti-D injection because passive prophylactic antibody may appear in later samples. There is no single routine serological test that reliably labels a detected anti-D result as passive or immune; interpretation needs the laboratory, timing and trend.
Fetal cells entering maternal circulation or previous transfusion can expose an antigen absent from maternal cells, producing an immune response that persists into later pregnancies.
IgG antibodies against D, c, K and other antigens can threaten a fetus carrying the target antigen, whereas many cold-reactive IgM antibodies do not cross the placenta.
Maternal IgG reaches the fetal circulation and binds antigen-positive red cells, leading to immune destruction and progressive anaemia in susceptible pregnancies.
Some antibodies, particularly anti-K, impair red-cell precursor production as well as promoting destruction, which alters the relationship between anaemia and bilirubin production.
Falling blood viscosity and compensatory cardiac output increase MCA velocity; severe sustained anaemia can progress to cardiac failure, hydrops and fetal death.
Identify anti-D, anti-c, anti-K and other specificities explicitly; a D-positive maternal group does not exclude antibodies against another red-cell antigen.
Previous fetal transfusion, hydrops, exchange transfusion or significant neonatal anaemia signals higher risk even when the current concentration is below a conventional threshold.
Raised MCA velocity, cardiomegaly, hydrops or deteriorating fetal status may indicate anaemia requiring invasive-treatment assessment at an experienced centre.
A recent anti-D injection may produce a detectable result without sensitisation, but timing, dose and serial laboratory interpretation are needed before excluding immune antibody.
Fetomaternal haemorrhage, parvovirus infection and other fetal disorders can also produce anaemia or hydrops, so abnormal Doppler is not by itself proof of alloimmune disease.
Some antibodies mainly complicate maternal crossmatching while others cause fetal or neonatal disease; the exact specificity and immunoglobulin class determine the appropriate pathway.
Recent documented prophylaxis can explain detectable anti-D, but assumptions based only on a weak reaction risk missing sensitisation that requires fetal monitoring.
Progressive anaemia can cause hydrops, cardiac dysfunction, stillbirth or a need for repeated intrauterine transfusions with the risks of an invasive fetal procedure.
Bilirubin may rise after birth and anaemia may persist or emerge later, requiring phototherapy, transfusion or other neonatal treatment based on serial assessment.
Multiple or unusual antibodies can make suitable units difficult to source, so an uncommunicated antibody history can create avoidable delay during maternal or neonatal haemorrhage.
Anti-K may suppress fetal erythroid precursors as well as causing immune destruction, so haemoglobin can fall without a proportionately striking bilirubin signal.
BSH recommends referral when anti-K is identified and uses a titre of at least 1:4 as a suggested threshold for serial MCA surveillance in an at-risk fetus.
The 2025 BSH correction clarifies that its high-risk algorithm concerns lower-case anti-c; antibody capitalisation identifies different antigens and must be preserved.
A D-negative patient with anti-K or another non-D antibody may still need D prophylaxis unless immune anti-D is established or validated fetal testing removes the indication.
Assuming detectable anti-D is passive solely because an injection appears somewhere in the notes without verifying date, dose and administration.
Withholding indicated D prophylaxis because a D-negative patient has an antibody directed against a different antigen.
Using a low anti-K titre to postpone specialist referral or failing to consider fetal antigen status.
Planning delivery without telling transfusion and neonatal services about antibodies that may complicate compatible blood provision or newborn care.
Your practice draft is saved in this browser.
A patient’s booking screen identifies anti-K for the first time. The reported titre is low and fetal antigen status is unknown. What is the appropriate next action?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Fetal risk depends on the antigen as well as the antibody. Non-invasive fetal genotyping can identify relevant fetal antigen status through a specialist laboratory, with timing and repeat requirements that depend on the antigen and assay. Paternal testing can sometimes inform probability, but consent and sensitive handling of biological parentage are essential. A reliable antigen-negative fetal result can substantially alter surveillance, whereas uncertain results should not be used as reassurance. The specialist service coordinates which samples are still needed when MCA Doppler surveillance becomes the main assessment.
Anti-D immunoglobulin is prevention for eligible patients who have not developed immune anti-D. It should be offered through routine antenatal and event-related pathways with the exact licensed product and dose documented. Antibodies to another antigen do not themselves remove the need for D prophylaxis in a D-negative patient. After a relevant sensitising event, give indicated prophylaxis promptly, usually within 72 hours, and contact transfusion if presentation is delayed. Fetomaternal haemorrhage testing quantifies whether additional product is needed; waiting for that result must not delay the initial indicated dose.
The neonatal plan is equally important. Maternal antibody can cause haemolysis or suppressed erythropoiesis after birth, so a vigorous newborn can still develop jaundice or later anaemia. Notify neonatal staff before delivery, obtain the appropriate cord and postnatal tests and arrange follow-up based on antibody, haemoglobin and bilirubin findings. Avoid automatic early discharge without considering the trajectory and previous fetal treatment. The maternity, fetal medicine, laboratory and neonatal teams need one shared plan that states who will act on each result.
This is a product-specific schedule; assess hypersensitivity and injection suitability, and do not mistake passive antibody detection for proof of established immunity.
D-Gam is for intramuscular administration; severe thrombocytopenia or another intramuscular contraindication requires an alternative suitable product and specialist advice.
If presentation is later, contact transfusion because some protection may still be possible; never delay the initial indicated dose while awaiting FMH quantification.